Aethlon Medical(US:AEMD)2024-08-14 22:45Financial Data and Key Metrics Changes - As of June 30, 2024, Aethlon Medical had a cash balance of approximately $9.1 million [16] - Consolidated operating expenses for the fiscal quarter ended June 30, 2024, were approximately $2.6 million, a decrease of approximately $800,000 or 24% compared to $3.4 million for the same quarter in 2023 [16][18] - Net loss decreased by approximately $700,000 to approximately $2.6 million in the fiscal quarter ended June 30, 2024, from approximately $3.3 million in the same quarter of 2023 [18] Business Line Data and Key Metrics Changes - The decrease in operating expenses was attributed to a $600,000 reduction in general and administrative expenses and a $300,000 decrease in professional fees, partially offset by a $100,000 increase in payroll and related expenses [16][17] - The decrease in G&A expenses was primarily due to a $447,000 reduction in supplies related to the Hemopurifier manufacturing [17] Market Data and Key Metrics Changes - The company is advancing its Hemopurifier technology, which has potential applications in oncology and infectious diseases, indicating a focus on addressing significant market needs [7][15] Company Strategy and Development Direction - Aethlon Medical is focused on the research and clinical development of its Hemopurifier, aiming to achieve measurable progress in oncology indications while reducing expenses [7][8] - The company is preparing for clinical trials in Australia, with expectations for increased activity and potential value-creating milestones in the near future [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving the company's objectives and noted that the clinical trial activities are expected to ramp up, which may lead to higher R&D expenses [22] - The company is actively evaluating its COVID-19 trial in India and is monitoring patient admissions, indicating a responsive approach to current health crises [15] Other Important Information - The Bellberry Human Research Ethics Committee granted full ethics approval for a clinical trial of the Hemopurifier in patients with solid tumors, valid until August 6, 2025 [9] - The primary endpoint of the clinical studies is safety, with a focus on monitoring adverse events and changes in lab tests for Hemopurifier-treated patients [12] Q&A Session Summary Question: Is the normalized operating expense a good run rate going forward? - Management indicated that while there are expected reductions in professional fees, increased clinical trial activities will likely offset some of these savings [22] Question: What is the training process for the clinical trial sites? - Management confirmed that site initiation visits are scheduled, and there will be ongoing support and training for the sites to ensure proper implementation of the Hemopurifier [24][25] Question: Has all necessary paperwork been completed for the clinical trials? - Management confirmed that all required paperwork for ethics committees has been submitted and is awaiting governance review [27]